Lamivudine Teva (Lamivudine)

Lamivudine is a nucleoside analogue that is taken up by cells and phosphorylated to its active triphosphate form. This active metabolite competitively inhibits the reverse transcriptase enzyme of HIV and the DNA polymerase of hepatitis B virus, causing premature termination of viral DNA synthesis and blocking replication.

The specific dose of Lamivudine Teva is determined by the prescribing clinician based on the patient’s age, weight, renal function, and the infection being treated. Healthcare providers follow established guidelines and adjust the regimen as needed; patients should follow the prescriber’s instructions exactly.

Safety data for lamivudine in pregnancy and lactation are limited. The drug may be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their healthcare professional.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for optimal viral suppression. Compared with agents such as tenofovir or abacavir, lamivudine generally has a favorable safety profile but may require dose adjustment in renal impairment and has specific interaction considerations.

Lamivudine Teva should be stored at room temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed to maintain product stability.

Lamivudine Teva is taken orally, usually as a tablet, with or without food. The exact administration schedule—once daily or divided doses—depends on the prescribing clinician’s regimen and the patient’s clinical situation.

Serious adverse events, though uncommon, include lactic acidosis, severe hepatotoxicity, pancreatitis, Stevens‑Johnson syndrome, and bone‑marrow suppression. Patients should be monitored for symptoms such as unexplained fatigue, abdominal pain, jaundice, or skin reactions and seek immediate medical attention if they occur.

Lamivudine Teva is contraindicated in individuals with known hypersensitivity to lamivudine or any of its excipients. It should also be avoided in patients with severe hepatic impairment or those receiving contraindicated drug combinations unless closely supervised by a healthcare professional.